Back to top
more

Celanese (CE)

(Delayed Data from NYSE)

$157.60 USD

157.60
442,701

+3.11 (2.01%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $157.65 +0.05 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Chemical - Specialty

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Celanese (CE) & Glaukos Join Forces for Glaucoma Treatment

by Zacks Equity Research

Celanese (CE) partners with Glaukos to provide VitalDose for sustained release treatment for glaucoma.

Is Invesco S&P 500 Equal Weight Materials ETF (RTM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RTM

Is First Trust Large Cap Value AlphaDEX ETF (FTA) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FTA

Here's Why You Should Retain Celanese (CE) in Your Portfolio

by Zacks Equity Research

Celanese (CE) gains on productivity actions, investments in high-return organic projects and synergies of acquisitions.

Is First Trust Large Cap Core AlphaDEX ETF (FEX) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FEX

Should You Invest in the Invesco S&P 500 Equal Weight Materials ETF (RTM)?

by Zacks Equity Research

Sector ETF report for RTM

Should First Trust Large Cap Core AlphaDEX ETF (FEX) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FEX

Is First Trust Multi Cap Value AlphaDEX ETF (FAB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FAB

Should First Trust Large Cap Value AlphaDEX ETF (FTA) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FTA

Celanese (CE) Partners With Alessa for Drug Delivery System

by Zacks Equity Research

Celanese (CE) forms an alliance with Alessa Therapeutics to develop an innovative drug delivery system for oncology patients.

Celanese (CE) & Mitsui Ink New Partnership, Extend Fairway JV

by Zacks Equity Research

Celanese (CE) joins forces with Mitsui to form a new Food Ingredient joint venture to strengthen its strategic partnership with the latter.

Celanese's (CE) Earnings and Revenues Miss Estimates in Q4

by Zacks Equity Research

Input cost inflation, supply chain disruptions and consumer destocking weigh on fourth-quarter performance of Celanese (CE).

Celanese (CE) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Celanese (CE) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Celanese (CE) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Celanese (CE) delivered earnings and revenue surprises of -7.69% and 2.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Mayur Thaker headshot

Stocks Jittery With Pesky Inflation and Weak Economic Data

by Mayur Thaker

EPS Estimate revisions, inflation and unemployment are the trifecta to solving the market's next move.

Celanese (CE) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Softness in demand in Europe & Asia, weaker volumes and elevated energy & logistic cost are expected to have put a dent in Celanese's (CE) Q4 performance.

AdvanSix (ASIX) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

AdvanSix (ASIX) delivered earnings and revenue surprises of -18.59% and 14.51%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Celanese (CE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Celanese (CE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MP Materials (MP) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

MP Materials' (MP) fourth-quarter 2022 results are likely to reflect benefits of increased realized pricing, offset by higher raw material and logistic costs.

Teck Resources (TECK) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Teck Resources' (TECK) Q4 results are likely to reflect low metal prices and a year-over-year drop in sales volumes for steelmaking coal, copper and zinc as well as inflated costs.

What's in Store for Piedmont Lithium (PLL) This Earnings Season?

by Zacks Equity Research

Piedmont Lithium's (PLL) fourth-quarter 2022 results are likely to reflect exploration and mine development costs as well as higher general and administrative expenses.

Vale (VALE) to Report Q4 Earnings: What to Expect?

by Zacks Equity Research

Vale's (VALE) fourth-quarter 2022 results are likely to reflect the impact of lower iron ore, copper and nickel prices as well as higher diesel and freight costs.

Barrick (GOLD) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Barrick's (GOLD) fourth-quarter results are expected to reflect the benefits of improved gold prices and strong gold production.

Will Strong Lithium Prices Drive Albemarle's (ALB) Q4 Earnings?

by Zacks Equity Research

Albemarle (ALB) is likely to have benefited from strong lithium volumes and prices and its cost-reduction actions in the fourth quarter.

The Zacks Analyst Blog Highlights Albemarle, Celanese, Huntsman and Westlake

by Zacks Equity Research

Albemarle, Celanese, Huntsman and Westlake are included in this Analyst Blog.